Int. J. Mol. Sci. 2012, 13(2), 2208-2218; doi:10.3390/ijms13022208
Article

A Novel LMP1 Antibody Synergizes with Mitomycin C to Inhibit Nasopharyngeal Carcinoma Growth in Vivo Through Inducing Apoptosis and Downregulating Vascular Endothelial Growth Factor

1 Department of Otolaryngology—Head and Neck Surgery, The Second Affiliated Hospital of Nanjing Medical University, 121 Jiangjiayuan, Nanjing 210011, China 2 Department of Otolaryngology—Head and Neck Surgery, Jiangsu Province Official Hospital, 65 Jiangsu Road, 210029 Nanjing, China 3 The Key Laboratory of Cancer Biomarkers, Prevention & Treatment Cancer Center and The Key Laboratory of Antibody Technique of Ministry of Health, Nanjing Medical University, 140 Hanzhong Road, Nanjing 210029, China 4 Huadong Medical Institute of Biotechniques, 293 Zhongshandong Road, Nanjing 210002, China
* Authors to whom correspondence should be addressed.
Received: 17 January 2012; in revised form: 14 February 2012 / Accepted: 15 February 2012 / Published: 17 February 2012
PDF Full-text Download PDF Full-Text [330 KB, Updated Version, uploaded 21 February 2012 15:06 CET]
The original version is still available [330 KB, uploaded 17 February 2012 12:40 CET]
Abstract: Combined therapy emerges as an attractive strategy for cancer treatment. The aim of this study was to investigate the inhibitory effects of mitomycin C (MMC) combined with a novel antibody fragment (Fab) targeting latent membrane protein 1 (LMP1) on nasopharyngeal carcinoma (NPC) xenograft nude mice. The inhibitory rates of MMC (2 mg/kg), Fab (4 mg/kg), MMC (2 mg/kg) + Fab (4 mg/kg), and MMC (1 mg/kg) + Fab (4 mg/kg) were 20.1%, 7.3%, 42.5% and 40.5%, respectively. Flow cytometry analysis showed that the apoptotic rate of xenograft tumor cells in the MMC and Fab combination group was 28 ± 4.12%, significantly higher than the MMC (2 mg/kg) group (P < 0.01). Immunohistochemical staining showed that VEGF expression in NPC xenografts was significantly inhibited in the combination group compared to the Fab (4 mg/kg) group (P < 0.05). In conclusion, both MMC and Fab could inhibit NPC xenograft tumor growth in vivo and combination therapy showed apparent synergistic anti-tumor effects, which may be due to the induction of tumor cell apoptosis and the downregulation of VEGF expression. These results suggest that the novel combined therapy utilizing traditional chemotherapeutics and antibody-targeted therapy could be a promising strategy for the treatment of NPC.
Keywords: mitomycin C; latent membrane protein 1; antibody targeted therapy; nasopharyngeal carcinoma; apoptosis; VEGF

Article Statistics

Load and display the download statistics.

Citations to this Article

Cite This Article

MDPI and ACS Style

Mao, Y.; Zhang, D.-W.; Wen, J.; Cao, Q.; Chen, R.-J.; Zhu, J.; Feng, Z.-Q. A Novel LMP1 Antibody Synergizes with Mitomycin C to Inhibit Nasopharyngeal Carcinoma Growth in Vivo Through Inducing Apoptosis and Downregulating Vascular Endothelial Growth Factor. Int. J. Mol. Sci. 2012, 13, 2208-2218.

AMA Style

Mao Y, Zhang D-W, Wen J, Cao Q, Chen R-J, Zhu J, Feng Z-Q. A Novel LMP1 Antibody Synergizes with Mitomycin C to Inhibit Nasopharyngeal Carcinoma Growth in Vivo Through Inducing Apoptosis and Downregulating Vascular Endothelial Growth Factor. International Journal of Molecular Sciences. 2012; 13(2):2208-2218.

Chicago/Turabian Style

Mao, Yuan; Zhang, Da-Wei; Wen, Juan; Cao, Qing; Chen, Ren-Jie; Zhu, Jin; Feng, Zhen-Qing. 2012. "A Novel LMP1 Antibody Synergizes with Mitomycin C to Inhibit Nasopharyngeal Carcinoma Growth in Vivo Through Inducing Apoptosis and Downregulating Vascular Endothelial Growth Factor." Int. J. Mol. Sci. 13, no. 2: 2208-2218.

Int. J. Mol. Sci. EISSN 1422-0067 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert